The Granulomatosis with Polyangiitis Drug Market size is expected to grow at an annual average of 25% during 2022-2028. Granulomatosis with polyangiitis has a poor prognosis, mainly due to renal failure and GI (gastrointestinal)/alveolar hemorrhage. The prognosis has improved significantly with the introduction of cyclophosphamide therapy (CYC) and subsequent approval of rituximab (RTX) in both […]
